These three cases demonstrate the importance of recognizing CHS as a potential cause or contributing factor to death in cannabinoid user. Only 2 RCTs have investigated topical capsaicin and haloperidol use in patients with CHS 22, 32. Three retrospective studies were short-term, with small sample sizes, without a standardized reporting of outcomes and subject to the risk of …